Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance | Zendy

Michelle Doyle | Zendy; Lenka A. Vodstrcil | Zendy; Erica L. Plummer | Zendy; Ivette Aguirre | Zendy; Christopher K. Fairley | Zendy; Catriona S. Bradshaw | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance

Author(s) -

Michelle Doyle,

Lenka A. Vodstrcil,

Erica L. Plummer,

Ivette Aguirre,

Christopher K. Fairley,

Catriona S. Bradshaw

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa291

Subject(s) - mycoplasma genitalium , medicine , minocycline , doxycycline , quinolone , antimicrobial , mycoplasma , microbiology and biotechnology , azithromycin , antibiotics , gynecology , chlamydia trachomatis , biology

In the era of increasing macrolide- and quinolone-resistant Mycoplasma genitalium (MG), we report the efficacy of 2 nonquinolone antimicrobials in patients with limited treatment options. Pristinamycin + doxycycline cured 75% (95% CI, 64%–85%), and minocycline cured 71% (95% CI, 54%–85%) of cases. These data provide useful estimates to inform clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research